BULGARI
23.5.2022 09:40:10 CEST | Business Wire | Press release
In the presence of Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture and Arts Authority (Dubai Culture) and Member of the Dubai Council, Bulgari, the leading Italian brand in the world of jewellery and luxury, and in partnership with Dubai Culture, announced the winner of the first edition of the Bulgari Contemporary Art Award during a ceremony held at the Italy Pavilion at Expo 2020 Dubai. The winner was chosen from a shortlist of three art pieces selected by the award’s jury.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005313/en/
The ceremony was attended by His Excellency Giuseppe Finocchiaro, Consul-General, Italian Consulate (Dubai); Paolo Glisenti, Italy’s Commissioner General for Expo 2020 Dubai; Jean Christophe Babin, Group CEO of Bulgari; Lucia Boscaini, Brand Curator at Bulgari; Her Excellency Hala Badri, Director General of Dubai Culture; and Dr Saeed Mubarak bin Kharbash, CEO of the Arts and Literature Sector at Dubai Culture .
A panel of three experts — Giuseppe Moscatello, Nujoom Alghanem and Patricia Millns FRSA — visited the exhibition held from 3 to 8 February at the Van de Goudenberg Art Gallery in the Dubai International Financial Centre to celebrate the participating works. Among the 15 artworks, the committee shortlisted three artists: Juma AlHaj (UAE), Dubai-based Kamal Alzubi (Jordan), and Dubai-based artist Nima Nabavi (Iranian-American), who the jury selected for the winning artwork.
Nima Nabavi received a trophy that celebrates the aesthetic and cultural dialogue between Rome and Dubai by combining a silhouette inspired by Bulgari’s iconic doorways and storefronts with architectural ornaments inspired from Dubai’s Al Fahidi and Al Shindagha Historical Neighbourhoods. The trophy was designed by Emirati designer Kamla AlOlama and produced by Asateer, an Emirati studio founded by Mohammed AlSuwaidi specialising in contemporary products that reflect the rich Emirati heritage.
The trophy uses materials with great cultural significance. A frame is fabricated from the rich woods of the UAE’s national tree, Al Ghaf, an emblem of heritage and perseverance. The design also incorporates native mother-of-pearl inlaid motifs and brass.
Nima Nabavi expressed his happiness at winning the award and thanked Bulgari and Dubai Culture for giving him the opportunity to share his artistic vision. He also extended his gratitude to the experts and jury for selecting his work for the award.
The winning artwork was exhibited at the Italy Pavilion in Expo 2020. The artist was also offered the opportunity to experience Rome through the eyes of Bulgari as part of a week-long journey through the brand’s universe. He will experience the beauty of Bulgari’s colourful gems and visit the DomvsAvrea museum space in the Maison’s flagship store in Rome, as well as attend workshops with Bulgari designers and exclusive tours of historical sites and cultural locations particularly linked with Bulgari’s patronage, initiatives and inspiration. In addition, the winning piece will be exhibited at venues associated with Dubai Culture and Bulgari, according to a pre-defined schedule.
Launched in July 2021, the Bulgari Contemporary Art Award opened the door for UAE national and resident artists to submit artworks under the theme ‘Beauty Connects People’ that had them creatively express how beauty connects people and how cities like Dubai and Rome are linked by their inspirational beauty and innovation.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom